Hong-Qun Tang
Hong-Qun Tang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Fan Niu
Data Governance Center, Nanchang People’s Hospital, Nanchang, China
1 shared publication - Fan Wang
Data Governance Center, Nanchang People’s Hospital, Nanchang, China
1 shared publication - Hao Fang
School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China
1 shared publication Hong-Liang Ji
Department of Pathology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, China
1 shared publicationHui Xu
School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China
1 shared publicationJian-Hong Tu
Pathology Department, The Nanchang People’s Hospital, Nanchang, China
1 shared publication
Latest Publications
- Open Access
- 24 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1066-1080
Prediction of neoadjuvant therapy response in breast cancer based on interpretable artificial intelligence
Background: To develop an AI-based predictive model for neoadjuvant therapy (NAT) efficacy in breast cancer, we integrated multimodal data and analyzed tumor microenvironment (TME) features to provide interpretability. Methods: We retrospectively analyzed H&E-stained whole-slide images (WSIs) from a multicenter cohort of breast cancer patients receiving NAT to develop an AI predictive model. The cohort was stratified into training, test, internal validation, and external validation sets. Feature extraction used UNI and classification employed a multiple instance learning (MIL) framework. Model performance was evaluated via ROC curve analysis (AUC, precision, specificity, recall). Molecular mechanisms underlying model predictions were explored using TCGA multimodal data, integrating differential gene expression profiling with pathway enrichment analysis (GO, KEGG). TME component correlations with model scores were also investigated. Results: The AI model demonstrated robust discriminative capacity across three residual cancer burden (RCB)-based classification tasks in 826 patients from two centers, achieving peak performance in subtask 2 (NAT-sensitive: RCB 0–1 vs. NAT-resistant: RCB 2–3). For subtask 2, AUCs were 0.901 (training), 0.858 (test), 0.808 (internal validation), and 0.819 (external validation). Molecular analysis linked the model’s predictive efficacy to tumor cell cycle processes. TME analysis revealed positive correlations between model scores and activated immune cells (M0/M1 macrophages, dendritic cells), and negative correlations with inhibitory cells (M2 macrophages, resting mast cells). Crucially, the model’s predictive scores were closely related to tumor-infiltrating lymphocytes (TILs), with spatial colocalization observed between classification weights and TILs distribution. Significant differences in TILs levels occurred across model score strata, validating the model’s biological plausibility in predicting NAT response mechanisms. Conclusion: We developed an interpretable AI model that predicts response to neoadjuvant therapy in breast cancer using H&E slides. The model’s predictions are biologically interpretable, correlating with TME dynamics and spatial TIL patterns, offering a novel strategy for personalizing NAT treatment strategies.
- 24 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1066-1080
Open AccessPrediction of neoadjuvant therapy response in breast cancer based on interpretable artificial intelligence
Background: To develop an AI-based predictive model for neoadjuvant therapy (NAT) efficacy in breast cancer, we integrated multimodal data and analyzed tumor microenvironment (TME) features to provide interpretability. Methods: We retrospectively analyzed H&E-stained whole-slide images (WSIs) from a multicenter cohort of breast cancer patients receiving NAT to develop an AI predictive model. The cohort was stratified into training, test, internal validation, and external validation sets. Feature extraction used UNI and classification employed a multiple instance learning (MIL) framework. Model performance was evaluated via ROC curve analysis (AUC, precision, specificity, recall). Molecular mechanisms underlying model predictions were explored using TCGA multimodal data, integrating differential gene expression profiling with pathway enrichment analysis (GO, KEGG). TME component correlations with model scores were also investigated. Results: The AI model demonstrated robust discriminative capacity across three residual cancer burden (RCB)-based classification tasks in 826 patients from two centers, achieving peak performance in subtask 2 (NAT-sensitive: RCB 0–1 vs. NAT-resistant: RCB 2–3). For subtask 2, AUCs were 0.901 (training), 0.858 (test), 0.808 (internal validation), and 0.819 (external validation). Molecular analysis linked the model’s predictive efficacy to tumor cell cycle processes. TME analysis revealed positive correlations between model scores and activated immune cells (M0/M1 macrophages, dendritic cells), and negative correlations with inhibitory cells (M2 macrophages, resting mast cells). Crucially, the model’s predictive scores were closely related to tumor-infiltrating lymphocytes (TILs), with spatial colocalization observed between classification weights and TILs distribution. Significant differences in TILs levels occurred across model score strata, validating the model’s biological plausibility in predicting NAT response mechanisms. Conclusion: We developed an interpretable AI model that predicts response to neoadjuvant therapy in breast cancer using H&E slides. The model’s predictions are biologically interpretable, correlating with TME dynamics and spatial TIL patterns, offering a novel strategy for personalizing NAT treatment strategies.